ASCO 2017

Patients with a germline BRCA mutation were at a reduced risk for progression when treated with olaparib for HER2-metastatic breast cancer.

When combined with an aromatase inhibitor, dual HER2 blockade shows superior PFS compared with lapatinib or trastuzumab alone in some women with breast cancer.

The antibody drug conjugate, T-DM1, when used alone or in combination with pertuzumab, did not significantly improve overall survival compared with trastuzumab and a taxane.

Evidence suggests that combining palbociclib with endocrine therapy can reverse acquired resistance to endocrine therapy in breast cancer.

Data from PALOMA-1/TRIO-18 showed that combining palbociclib and letrozole did not significantly improve survival compared with letrozole alone among patients with breast cancer.

Patients with breast cancer who progress on endocrine therapy and are then treated with abemaciclib and fulvestrant have a 45% decreased risk for progression.